The most compelling finding is that while single-agent anti-PD-1 antibody therapy is minimally effective in this TNBC model, combination therapy of anti-PD-1 antibody with buparlisib inhibited tumor growth in 100% of the mice. Here, PDCD1 is linked to neoplasm.